Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19312483 | 0.85 | KDM4C (0.42) | NPBWR1SCDCBFBKMT2A | |
| SCHEMBL8501874 | 0.79 | NPBWR1 (0.47) | NPBWR1SCDCBFBBRD4MEN1 | |
| SCHEMBL10969202 | 0.78 | FABP6 (0.47) | NPBWR1SCDCBFBMEN1KMT2A | |
| SCHEMBL8501872 | 0.78 | NPBWR1 (0.46) | NPBWR1SCDCBFBMEN1KMT2A | |
| SCHEMBL8498390 | 0.78 | NPBWR1 (0.46) | NPBWR1SCDPTGS2CBFBMEN1 | |
| SCHEMBL23676506 | 0.75 | KDM4E (0.51) | NPBWR1SCDCBFBBRD4MEN1 | |
| SCHEMBL16134723 | 0.75 | L3MBTL1 (0.57) | NPBWR1SCDCBFBMEN1KMT2A | |
| SCHEMBL31578181 | 0.75 | ALDH1A1 (0.50) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22531493 | 0.74 | CACNA1H (0.44) | NPBWR1SMN1; SMN2SCDCBFBMEN1 | |
| SCHEMBL27766822 | 0.74 | ALDH1A1 (0.52) | NPBWR1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-3214076-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAR2B, PRKAR2A, PRKAG3 | NPBWR1 466/4885SMN1; SMN2 2948/4885SCD 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.